Pharmacological targeting of the PI3K/mTOR pathway by specific inhibitors in human nasopharyngeal, colorectal, and glioma cells was effective in diminishing tumor hypoxia by reducing mitochondrial oxygen consumption [38]. This evidence concerns the gene MTOR and central nervous system cancer.